CN104583422A - 标志物在诊断和治疗前列腺癌中的用途 - Google Patents

标志物在诊断和治疗前列腺癌中的用途 Download PDF

Info

Publication number
CN104583422A
CN104583422A CN201380045178.1A CN201380045178A CN104583422A CN 104583422 A CN104583422 A CN 104583422A CN 201380045178 A CN201380045178 A CN 201380045178A CN 104583422 A CN104583422 A CN 104583422A
Authority
CN
China
Prior art keywords
keratin
prostate cancer
level
sample
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380045178.1A
Other languages
English (en)
Chinese (zh)
Inventor
N·R·纳莱恩
R·萨兰加拉詹
V·K·维施努达斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bo Ge Co Ltd
Original Assignee
Bo Ge Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bo Ge Co Ltd filed Critical Bo Ge Co Ltd
Publication of CN104583422A publication Critical patent/CN104583422A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380045178.1A 2012-06-27 2013-06-27 标志物在诊断和治疗前列腺癌中的用途 Pending CN104583422A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201261665201P 2012-06-27 2012-06-27
US61/665,201 2012-06-27
US201261672090P 2012-07-16 2012-07-16
US61/672,090 2012-07-16
US201261673094P 2012-07-18 2012-07-18
US61/673,094 2012-07-18
US201261702523P 2012-09-18 2012-09-18
US61/702,523 2012-09-18
US201261718081P 2012-10-24 2012-10-24
US201261718080P 2012-10-24 2012-10-24
US201261718064P 2012-10-24 2012-10-24
US61/718,064 2012-10-24
US61/718,080 2012-10-24
US61/718,081 2012-10-24
PCT/US2013/048373 WO2014004931A1 (en) 2012-06-27 2013-06-27 Use of markers in the diagnosis and treatment of prostate cancer

Publications (1)

Publication Number Publication Date
CN104583422A true CN104583422A (zh) 2015-04-29

Family

ID=49783880

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380045178.1A Pending CN104583422A (zh) 2012-06-27 2013-06-27 标志物在诊断和治疗前列腺癌中的用途

Country Status (15)

Country Link
US (3) US20140038838A1 (https=)
EP (1) EP2867375B1 (https=)
JP (2) JP6352909B2 (https=)
KR (1) KR20150023904A (https=)
CN (1) CN104583422A (https=)
AU (1) AU2013284448B2 (https=)
BR (1) BR112014032728A2 (https=)
CA (1) CA2877721A1 (https=)
EA (1) EA201492284A1 (https=)
ES (1) ES2720763T3 (https=)
IL (1) IL236482A0 (https=)
MX (1) MX360236B (https=)
NZ (1) NZ703411A (https=)
SG (1) SG11201408651TA (https=)
WO (1) WO2014004931A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109608537A (zh) * 2018-12-12 2019-04-12 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p2及其应用
CN109608536A (zh) * 2018-12-12 2019-04-12 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p3及其应用
CN110114086A (zh) * 2016-06-03 2019-08-09 埃特彼塞斯公司 用于使用前列腺癌相关抗原肿瘤疫苗接种的组合物和方法
CN114134223A (zh) * 2021-12-02 2022-03-04 青岛市中心血站 一种用于丙型肝炎病毒相关肝纤维化的血液检测试剂盒
CN114460297A (zh) * 2022-01-17 2022-05-10 珠海中科先进技术研究院有限公司 一种用于检测血液中循环前列腺上皮细胞的免疫荧光试剂盒及其使用方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY193914A (en) 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
AU2015215008B2 (en) * 2014-02-05 2019-11-28 Fujirebio Diagnostics Ab Composition and method for detecting malignant neoplastic disease
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
DK3123381T3 (da) 2014-03-28 2023-11-27 Opko Diagnostics Llc Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
US10539566B2 (en) * 2014-12-08 2020-01-21 Berg Llc Use of markers including filamin A in the diagnosis and treatment of prostate cancer
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
EP3490677A4 (en) * 2016-07-07 2020-05-13 Berg LLC LIPID, PROTEIN AND METABOLITE MARKER FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
WO2018189292A1 (en) * 2017-04-13 2018-10-18 Institut National De La Sante Et De La Recherche Medicale Biomarkers of castration-resistant prostatic cells
KR102405789B1 (ko) * 2018-08-24 2022-06-07 고려대학교 세종산학협력단 키누레닌 경로 대사체를 포함하는 전립선암 진단용 바이오마커 조성물
KR102497196B1 (ko) * 2020-09-08 2023-02-07 (주)유로테크 전립선암 진단 점수 계산 방법 및 그 용도

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076614A2 (de) * 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
WO2007071947A1 (en) * 2005-12-19 2007-06-28 University Of Hull Cancer screening test
WO2008121307A2 (en) * 2007-03-28 2008-10-09 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
US20090215636A1 (en) * 2005-05-25 2009-08-27 Krizman David B Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2011040532A1 (ja) * 2009-10-02 2011-04-07 学校法人 久留米大学 癌患者に対する免疫療法の治療効果および／または免疫療法後の予後の予測方法、ならびに該方法に用いる遺伝子セットおよびキット
US20110236903A1 (en) * 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2011149402A2 (en) * 2010-05-27 2011-12-01 Atlas Antibodies Ab Prostate cancer biomarkers
WO2012021969A1 (en) * 2010-08-16 2012-02-23 Mount Sinai Hospital Markers of the male urogenital tract

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942999C2 (de) 1989-12-27 1997-12-18 Progen Biotechnik Gmbh Verfahren zum Nachweis von malignen Erkrankungen
DE4208422A1 (de) 1992-03-16 1993-09-30 Boehringer Mannheim Gmbh Verfahren zum Nachweis von Mikrometastasen ekto- oder entodermaler Tumoren
DE69739909D1 (de) 1996-03-26 2010-07-29 Michael S Kopreski Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
US6107103A (en) * 1996-10-15 2000-08-22 Procyon Bropharma Inc. Assay for PSP94 protein
WO1999014372A1 (en) 1997-09-15 1999-03-25 Abbott Laboratories Reagents and methods useful for detecting diseases of the urinary tract
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
JP2002527489A (ja) 1998-10-22 2002-08-27 キュラゲン コーポレイション 腎疾患および関連疾患に対する予想および治療的遺伝子およびタンパク質
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
CA2404431C (en) 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
WO2002014500A2 (en) 2000-08-16 2002-02-21 Chiron Corporation Human genes and gene expression products
WO2002060317A2 (en) 2001-01-30 2002-08-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
ATE429511T1 (de) 2001-03-01 2009-05-15 Epigenomics Ag Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene
ES2374311T3 (es) 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
WO2003097878A1 (en) 2002-05-21 2003-11-27 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
CA2499843A1 (en) 2002-09-25 2004-04-08 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
US20050259483A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US20040109863A1 (en) * 2002-12-04 2004-06-10 Peter Emtage Methods of therapy and diagnosis using targeting of cells that express Ly-9
DE10259703A1 (de) 2002-12-19 2004-07-08 Ivonex Gmbh Trennungsverfahren
WO2004058052A2 (en) 2002-12-20 2004-07-15 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
CA2519630A1 (en) 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
AU2004248120B2 (en) 2003-05-28 2009-04-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
WO2005012875A2 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
ITPD20030264A1 (it) 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
CN1743849A (zh) 2004-09-03 2006-03-08 上海透景生命科技有限公司 一种多肿瘤标志物并行检测的方法及试剂盒
US20060057127A1 (en) 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
US20060063214A1 (en) 2004-09-17 2006-03-23 Ozge Alper Methods and compositions for diagnosing neoplastic disease
EP1815021A2 (en) 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
CA2601157A1 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
EP1870455A4 (en) 2005-03-31 2010-01-20 Two Cells Co Ltd METHOD FOR DISTINCTION OF MESENCHYMAL STEM CELL USING MOLECULAR MARKER AND USE THEREOF
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
WO2006127860A2 (en) 2005-05-25 2006-11-30 Expression Pathology, Inc. Multiplex method for increased proteomic coverage from histopathologically processed biological samples using liquid tissue preparations
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1734118A1 (en) 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening
US7842466B1 (en) 2005-09-16 2010-11-30 Celera Corporation Colon disease targets and uses thereof
EP1938104A2 (en) 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
US20070122856A1 (en) 2005-11-10 2007-05-31 Aurelium Biopharma Inc. Tissue diagnostics for ovarian cancer
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
JP4968577B2 (ja) 2006-04-11 2012-07-04 エフ．ホフマン−ラ ロシュ アーゲー サイトケラチン１９（ＣＫ１９）ｍＲＮＡの迅速測定法、並びにそのためのプライマー及びプローブ
US20080003624A1 (en) 2006-06-13 2008-01-03 Sysmex Corporation Cancer metastasis determination method
WO2008013989A2 (en) 2006-07-27 2008-01-31 Cell Genesys, Inc. Methods and compositions for identifying a cellular immune response against prostate cancer
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
US8642349B1 (en) 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US8748108B2 (en) 2006-09-05 2014-06-10 Abbvie Inc. Biomarkers for identifying patient classes
WO2008029251A2 (en) 2006-09-07 2008-03-13 Universitatsklinikum Hamburg-Eppendorf Method for the detection of cancerous epithelial cells using released cytokeratins as markers for said cells
WO2008079269A2 (en) 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
CA2679664C (en) * 2007-03-02 2017-04-25 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP2559771A3 (en) 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US20090221004A1 (en) 2007-06-01 2009-09-03 Anita Lim Hong Caspase-cleavage anti-keratin antibodies for detection of apoptosis
EP2201134B1 (en) 2007-09-19 2018-11-21 The Research Foundation of State University of New York Gene expression signatures in enriched tumor cell samples
WO2009045389A2 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20090105167A1 (en) 2007-10-19 2009-04-23 Duke University Predicting responsiveness to cancer therapeutics
CN101896818B (zh) 2007-12-10 2016-01-20 霍夫曼-拉罗奇有限公司 作为癌症的标记物的Seprase
KR101810799B1 (ko) 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
US8008032B2 (en) 2008-02-25 2011-08-30 Cellective Dx Corporation Tagged ligands for enrichment of rare analytes from a mixed sample
AU2009270851A1 (en) 2008-07-16 2010-01-21 Dana-Farber Cancer Institute, Inc. Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof
WO2010011642A2 (en) 2008-07-21 2010-01-28 The Trustees Of The University Of Pennsylvania Methods and compositions using splicing regulatory proteins involved in tumor suppression
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
IT1391619B1 (it) 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
JP5172020B2 (ja) 2008-11-12 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのｐａｃａｐ
CA2747942C (en) 2008-12-22 2016-12-06 F. Hoffmann-La Roche Ag Armet as a marker for cancer
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
JP2012100536A (ja) 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
EP2403877B1 (en) 2009-03-06 2015-05-06 Klaus Tschira Stiftung GgmbH Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
US10815517B2 (en) 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
US9456558B2 (en) 2009-10-29 2016-10-04 King Kutter, Inc. Stump cutter
EP2335838B1 (en) 2009-12-18 2012-09-26 Deutsche Post AG Sorting system and method using a portable device
US20130095503A1 (en) 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
US20110177525A1 (en) 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
US8664472B2 (en) 2010-04-28 2014-03-04 Sesaco Corporation Pygmy sesame plants for mechanical harvesting
US8557777B2 (en) 2010-07-09 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
US20130217647A1 (en) * 2010-07-28 2013-08-22 Metabolon, Inc. Biomarkers for Prostate Cancer and Methods Using the Same
CA2808417A1 (en) * 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
CN106706914B (zh) 2010-09-09 2018-10-19 北京同为时代生物技术有限公司 用于诊断上皮源性癌症的血液标志物及单克隆抗体
CN103384824B (zh) 2010-12-06 2016-02-03 Thd股份公司 癌症诊断方法及其用途
AU2011349101A1 (en) 2010-12-24 2013-05-02 Map Diagnostics Pty Ltd Selective reaction monitoring (SRM) derived protein profiles for cancer and other pathologic entities
WO2012101283A1 (en) 2011-01-28 2012-08-02 Biosystems International Sas Combinatorial biomarkers for clinical applications in lung cancer patient management
WO2012116248A1 (en) 2011-02-24 2012-08-30 Massachusetts Institute Of Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
KR101320633B1 (ko) 2011-05-25 2013-10-30 엠앤디 (주) 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
EP2551673B1 (en) 2011-07-26 2016-01-20 Universidad de Salamanca Methods for the detection of cancer infiltration of the central nervous system
KR20140067001A (ko) 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
WO2013039477A1 (en) 2011-09-12 2013-03-21 University Of South Alabama Non-invasive methods of detecting target molecules
US20150152474A1 (en) 2012-03-09 2015-06-04 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
HK1208470A1 (en) 2012-03-29 2016-03-04 Biogen Ma Inc. Biomarkers for use in integrin therapy applications
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
TWI468519B (zh) 2012-09-05 2015-01-11 Univ China Medical Methods of detecting squamous cell carcinoma in vitro
US20150226744A1 (en) 2012-09-17 2015-08-13 Ait Austrian Institute Of Technology Gmbh Colon Cancer Diagnostic Method and Means
US9201061B2 (en) 2013-02-26 2015-12-01 Industry-University Cooperation Foundation Hanyang University KRT19 stabilizing HER2 and use thereof
EP2972375A2 (en) 2013-03-13 2016-01-20 Creatics LLC Methods and compositions for detecting pancreatic cancer
SE538211C2 (sv) 2013-04-05 2016-04-05 Idl Biotech Ab Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav
US20150079590A1 (en) 2013-09-18 2015-03-19 Beth Israel Deaconess Medical Center, Inc. Characterization and analysis of the composition and dynamics of the mammalian riboproteome
EP3047270A4 (en) 2013-09-20 2017-07-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076614A2 (de) * 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
US20090215636A1 (en) * 2005-05-25 2009-08-27 Krizman David B Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2007071947A1 (en) * 2005-12-19 2007-06-28 University Of Hull Cancer screening test
WO2008121307A2 (en) * 2007-03-28 2008-10-09 Cell Genesys, Inc. Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
US20110236903A1 (en) * 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2011040532A1 (ja) * 2009-10-02 2011-04-07 学校法人 久留米大学 癌患者に対する免疫療法の治療効果および／または免疫療法後の予後の予測方法、ならびに該方法に用いる遺伝子セットおよびキット
WO2011149402A2 (en) * 2010-05-27 2011-12-01 Atlas Antibodies Ab Prostate cancer biomarkers
WO2012021969A1 (en) * 2010-08-16 2012-02-23 Mount Sinai Hospital Markers of the male urogenital tract

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AYODELE A. ALAIYALAIYA，ET AL: "Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma hyperplasia and prostate adenocarcinoma", 《INTERNATIONAL JOURNAL OF ONCOLOGY》 *
CELESTIA S. HIGANO,ET AL: "Phase 1/2 Dose-Escalation Study of a GM-CSFSecreting，Allogeneic，Cellular Immunotherapy for Metastatic Hormone-Refractory Prostate Cancer", 《CANCER》 *
DAVID L. HUDSON,ET AL: "Epithelial Cell Differentiation Pathways in the Human Prostate:Identification of Intermediate Phenotypes by Keratin Expression", 《THE JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY》 *
DJORDJE ATANACKOVIC,ET AL: "Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma", 《HAEMATOLOGICA》 *
THOMAS ERNST,ET AL: "Decrease and Gain of Gene Expression Are Equally Discriminatory Markers for Prostate Carcinoma", 《AMERICAN JOURNAL OF PATHOLOGY》 *
TOBIAS-MACHADO M，ET AL: "Cytokeratin 19 expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients.", 《TUMORI》 *
ZACHAROULA PANTELEAKOU，ET AL: "Detection of Circulating Tumor Cells in Prostate Cancer Patients: Methodological Pitfalls and Clinical Relevance", 《MOL MED》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110114086A (zh) * 2016-06-03 2019-08-09 埃特彼塞斯公司 用于使用前列腺癌相关抗原肿瘤疫苗接种的组合物和方法
CN109608537A (zh) * 2018-12-12 2019-04-12 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p2及其应用
CN109608536A (zh) * 2018-12-12 2019-04-12 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p3及其应用
CN114134223A (zh) * 2021-12-02 2022-03-04 青岛市中心血站 一种用于丙型肝炎病毒相关肝纤维化的血液检测试剂盒
CN114134223B (zh) * 2021-12-02 2022-10-11 青岛市中心血站 一种用于丙型肝炎病毒相关肝纤维化的血液检测试剂盒
CN114460297A (zh) * 2022-01-17 2022-05-10 珠海中科先进技术研究院有限公司 一种用于检测血液中循环前列腺上皮细胞的免疫荧光试剂盒及其使用方法

Also Published As

Publication number Publication date
AU2013284448B2 (en) 2019-04-18
US20180031563A1 (en) 2018-02-01
NZ703411A (en) 2017-09-29
WO2014004931A1 (en) 2014-01-03
CA2877721A1 (en) 2014-01-03
BR112014032728A2 (pt) 2017-11-28
EP2867375A4 (en) 2016-06-01
JP6581247B2 (ja) 2019-09-25
JP2015523569A (ja) 2015-08-13
SG11201408651TA (en) 2015-01-29
US20140038838A1 (en) 2014-02-06
MX360236B (es) 2018-10-26
JP2018163164A (ja) 2018-10-18
HK1209792A1 (en) 2016-04-08
ES2720763T3 (es) 2019-07-24
EA201492284A1 (ru) 2015-11-30
IL236482A0 (en) 2015-02-26
EP2867375B1 (en) 2019-02-27
KR20150023904A (ko) 2015-03-05
MX2015000008A (es) 2015-04-10
US9797905B2 (en) 2017-10-24
JP6352909B2 (ja) 2018-07-04
AU2013284448A1 (en) 2015-01-22
EP2867375A1 (en) 2015-05-06
US20160178632A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
JP6581247B2 (ja) 前立腺癌の診断および処置におけるマーカーの使用
US20250123283A1 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
RU2596394C2 (ru) Маркеры для рака эндометрия
EP1601968B1 (en) Serum macrophage migration inhibitory factor (mif) as marker for prostate cancer
EP4182480B1 (en) Prognostic biomarkers for cancer
US9523690B2 (en) Biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma
US20150377889A1 (en) Galectin-3 as a marker for prostate cancer
KR102731352B1 (ko) 위암의 예후 예측 방법
WO2013096852A1 (en) Biomarkers of cancer
HK1209792B (en) Use of markers in the diagnosis and treatment of prostate cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150429

RJ01 Rejection of invention patent application after publication